Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are well known for improving heart failure-related outcomes but not ischemic cardiovascular events. To explore this further, researchers have investigated whether the dual SGLT1/2 inhibitor, sotagliflozin, could improve ischemic outcomes in 10,584 patients with type 2 diabetes, chronic kidney disease, and cardiovascular risk factors (median age – 69 years). The study found a significantly lower rate of total major adverse cardiovascular events (MACE) in the sotagliflozin group (4.8 vs.
6.3 events per 100 person-years; hazard ratio [HR] – 0.77) than in the placebo group. Sotagliflozin also significantly reduced the risk of myocardial infarction (HR – 0.68) and stroke (HR – 0.66) compared to placebo. These findings suggest that sotagliflozin provides cardiovascular benefits beyond heart failure by reducing the risk of myocardial…
